DiaMedica Therapeutics - DMAC Stock Forecast, Price & News

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

DiaMedica Therapeutics Price Performance

Shares of NASDAQ:DMAC traded down $0.01 during midday trading on Friday, hitting $1.69. The company's stock had a trading volume of 57,731 shares, compared to its average volume of 143,521. The business's fifty day simple moving average is $1.89 and its two-hundred day simple moving average is $2.32. DiaMedica Therapeutics has a 1 year low of $1.15 and a 1 year high of $4.82. The firm has a market capitalization of $44.68 million, a price-to-earnings ratio of -2.91 and a beta of 2.07.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Rating) last posted its quarterly earnings data on Wednesday, May 4th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.07. During the same quarter in the previous year, the business posted ($0.19) earnings per share. Analysts anticipate that DiaMedica Therapeutics will post -0.68 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on DMAC. Craig Hallum dropped their price objective on shares of DiaMedica Therapeutics from $18.00 to $12.00 and set a "buy" rating for the company in a report on Thursday, July 7th. Lake Street Capital lowered their target price on shares of DiaMedica Therapeutics from $14.00 to $8.00 and set a "buy" rating for the company in a research note on Thursday, July 7th. Finally, Oppenheimer lowered shares of DiaMedica Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Thursday, July 7th.

Insider Activity

In other news, major shareholder Koch Thomas Von bought 207,974 shares of DiaMedica Therapeutics stock in a transaction that occurred on Friday, July 8th. The shares were purchased at an average price of $1.33 per share, with a total value of $276,605.42. Following the completion of the acquisition, the insider now directly owns 2,855,827 shares in the company, valued at $3,798,249.91. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 5.60% of the company's stock.